Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study - Concepedia

Concepedia

Publication | Closed Access

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

134

Citations

28

References

2016

Year

Michael Bitzer, Marius Horger, Edoardo G. Giannini, Tom M. Ganten, Marcus A. Wörns, Jens T. Siveke, Matthias Dollinger, Guido Gerken, M. E. Scheulen, Henning Wege,

Journal of Hepatology

Shelter StudyOncologyHepatologyMedicineLiver CancerCancer TreatmentSecond-line TherapyPharmacologyRadiation OncologyHepatocellular CarcinomaAdvanced Hepatocellular Carcinoma

References

	Year	Citations

Page 1

Page 1